Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Like the Parry article says nothing about two licenses, and the up lists. Both articles are worth reading. But remember unrestricted or not there are copanies that have billions of shares and with good news their stock goes up. Also I feel up lists will be in late july or early august. But remember there will be few licenses out there and Tweed according to one article is bleeding. Take over a chocolate factory with in my opinion mold issues presents a big problem not that easy to rememdy.
They shipped two weeks after they received the full license. It appears they received the preliminary before the law went into effect on April 1. Correct me if I am wrong.
Interesting Article:
Cramer giddy about overseas marijuana stock
Lee Brodie | @LeeBrod
14 Hours Ago
CNBC.com
163
SHARES
3
COMMENTSJoin the Discussion
(Click for video linked to a searchable transcript of this Mad Money segment)
Forget the lighthearted puns about a new kind of Street high, Jim Cramer believes there's serious opportunity in a marijuana stock.
It's GW Pharmaeuticals.
Cramer is a fan of this company, in particular, because it isn't simply a bet on more states approving medical marijuana as a treatment for patients fighting cancer.
Instead, this U.K.-based company is at the forefront of developing new drugs from compounds found in cannabis, or marijuana plants.
Deux| Photodisc | Getty Images
"And I think few doctors want to write anyone a prescription for a joint, not just because the stuff is still illegal where the Federal government's concerned, but mostly because, while smoking weed may help people who have cancer or glaucoma, it's simply not what most American doctors would consider medicine."
Instead, Cramer thinks doctors are much more comfortable writing prescriptions for pills or other types of conventional medicine. Therefore he thinks drugs, whose active ingredients are derived from marijuana will be much more palatable to the entire American medical system.
And if any company has a strong pipeline of cannabis derived drugs, it's GW Pharma.
"First, they've already gotten approval for their lead drug, Sativex, a mouth spray for multiple sclerosis spasms, in about 25 foreign countries," Cramer said. "And GW is also studying Sativex as a treatment for cancer pain. If the drug can get approved in the United States, it could be huge for the company, because they've licensed much of the overseas rights to Bayer and Novartis, but in America, Sativex belongs to them."
As promising as that may be, it's this second drug that Cramer called a real game changer. It's Epidiolex, "a cannabis based treatment for epilepsy and Dravet syndrome, a rare but severe form of pediatric epilepsy."
Cramer said the drug is currently starting phase II trials and just a few days ago, the company released strong safety and efficacy data.
"The numbers showed that after 12 weeks of treatment, 48 percent of patients saw at least a 50 percent reduction in seizure frequency, while 41 percent saw a 70 percent reduction. And at the end of the study, 15 percent of those patients were seizure-free. Those are fabulous results."
"Although it will be years before this drug can be approved, already there are peak sales forecasts of as much as $3.4 billion by 2024," Cramer added.
All told, over the long-term, Cramer thinks GW Pharma shareholders may be facing significant opportunity.
-----------------------------------------------------------
Read more from Mad Money with Jim Cramer
These 2 companies executing perfectly
Stock with monster multi-year gains?
Wall Street, this BUD's for you!
-----------------------------------------------------------
"And if you're worried about investing in medical marijuana, let me tell you that a bunch of firms have endorsed this stock, including Bank of America, Cowen, Piper Jaffray and Leerink Swann," Cramer said.
Just one caveat, "the company is not yet profitable, however, they do have a nice, consistent revenue stream," Cramer said. Therefore, it's for speculation only.
Call Cramer: 1-800-743-CNBC
Questions for Cramer? madmoney@cnbc.com
Questions, comments, suggestions for the "Mad Money" website? madcap@cnbc.com
Lee Brodie
Lee Brodie
Producer
Dear polskigracz I would like to say anything I say on this site is based on my appraisal of the news. It is only a guesstimate. As to the license look at tweed it took 6 weeks we are past that now so another month being the end of the 2nd week in July seems clearly within the time the license should be approved. Secondly on Bills facebook he said he is busy doing trail runs for the license. Does that not mean we are close? I feel it does. Secondly Bill says on t his facebook Fitx is making the up lists a reality. We have John saying several weeks ago the paper work will not take that long, now we have Deloitte doing the audit. Also we have a number of share coming on in August. I believe August is the prime time for the up lists. Remember we should have plants in the ground and more news on hemp and research. I invest strictly on the news. If you disagree let me know I do not have private messaging. Thanks for your posts. Just remember this is my opinion nothing else.
We should find out license in early July and by August have the up-list or share restructure.
Thanks for your post to me, sometimes I get so up tight I become and impulsive and end of losing out. That has happened many times to me.
Let me say when you have lack of news and investors waiting for license news as in this case you have a great chance of dumping. As to the pump you see how the bleeding stopped once news came out. However, announcing and audit to me is not a pump. Thanks for question.
Once again I do my evaluations by the news. As time goes on there is a greater likelihood of dumping based on the lack of license news. Thanks for the analysis I will add that to my arsenal. On other hand I agree you from the point of view yes your right there was dumping.
I respectfully disagree. Pumps and dumps are one thing, but when investors tire of waiting for license it clearly effects the stock.
First the Suspensions, the news from Sec and Canada hurt the sector. Secondly everyone was expecting the license weeks ago. That hurt the momentum and the news came out when the stock was going down. Seems par for the course.
Excellent, excellent posts. Go fitx
At this point Day traders holiday. However, as we get closer and good news will pick up. Volume is excellent. It was slowing down until today. Go fitx
That is the nature of the beast. But we know now we are on solid ground. Not just to do an audit but one that helps up lists. Bush, we are on our way.
Thanks for compliment.
You just picked the winner with the free cruise. We are on solid ground now we need the license. But there should be more news before that.
No doubt we need license but when it comes to investing this is the build up for legitimacy. Investors are more apt to invest in an MJ that is solid. Keep up the great work bush you are going to be very rewarded shortly.
Better Bushmantrader you should need oxygen on this great news. We should be way up now on any index. We have the winning team. Thanks Bush for your constant positive but true postings.
You are correct. A legitimate firm for an audit which we need to uplists. Once again we are on solid ground. But need license period.
Good analysis. License will be start, yet company still will have to turn a profit. First things first but with license a excellent buy.
No doubt investors are looking for solid stock because of the suspensions. I believe if Fitx gets the licenses we will be that solid stock. Gamble at this point is the license. I believe within the next few weeks we will get it.
You have it terry. Good posts.
Which article was that?
interesting article"
GW Pharma hits high as cannabis drug helps fight epilepsy
Reuters By By Ben Hirschler
7 hours ago
By Ben Hirschler
LONDON (Reuters) - An experimental cannabis drug has produced promising results in a small study of children with hard-to-treat epilepsy, sending shares in its British maker GW Pharmaceuticals to an all-time high.
The company, which grows cannabis under license at a secret location in Britain, is developing a range of so-called cannabinoid medicines. It already sells Sativex for spasticity caused by multiple sclerosis across Europe.
The latest findings for its new product Epidiolex follow an assessment of 27 children and young adults with treatment-resistant epilepsy who were given the drug in two U.S. hospitals under an expanded access program.
Epidiolex is given as a strawberry-lime flavored syrup twice a day. The medicine contains the cannabinoid CBD but none of the psychoactive ingredient THC that makes marijuana smokers high.
GW said on Tuesday that results after 12 weeks of therapy in the open-label study were "encouraging", with a reduction in seizure frequency of more than 50 percent. It now plans to start a Phase II/III clinical trial in the second half of the year.
Justin Gover, GW's chief executive, said he expected Epidiolex would be ready for submission to U.S. and European regulators in 2016.
Epidiolex has been granted “orphan drug” status by the U.S. Food and Drug Administration, which may ease its path to market and also offers GW additional exclusivity.
The designation reflects the unmet need for new approaches to help children with severe epilepsy syndromes such as Dravet and Lennox-Gastaut, where seizures often persist despite high doses of multiple anti-epileptic drugs.
Excitement over prospects for Epidiolex has been a driver for GW's shares, which have surged since the company tapped into a new U.S. shareholder base by listing on Nasdaq a year ago.
"It has become a central part of our valuation - there is no doubt about that," Gover said in an interview. "That reflects a number of reasons: the fact there is so much interest among physicians and patients, the fact it is an orphan development program and the fact we own all the commercial rights worldwide."
Shares in GW gained 15 percent to a record high of 430 pence by 1400 GMT.
Interest in cannabis has been spurred recently by the legalization of recreational marijuana shops in Colorado and Canada's move to create a federally regulated medical marijuana industry.
GW, however, distances itself from these developments by emphasizing its ability to extract key ingredients in cannabis for medical use, in the same way that pain-killing opioids have been developed from opium.
Its established product Sativex, which is given as an under-the-tongue spray, is currently available by prescription for MS spasticity in 11 countries and has received regulatory approval in an additional 13 countries.
Sativex is also in final-stage Phase III clinical development as a potential treatment of pain in people with advanced cancer.
Agreed good posts.
Great posts. Let's fix and get in their next.
I agree and once we get license investors will storm in for a nice rise.
Your being skeptical is why the Sec and Canada issued a stock warning. ABC MJ company announces they are in the MJ business and potential investors are not aware of the time and money and the risk involved. As we see even when you do everything you can you still have to wait for an inspection. Good Posts.
No doubt a risky venture. However, we are on our way of getting a license, very soon. But investors must realize just the security needed is enough to stop anybody. I am glad we are going to be within the first 20 something.
Realistic evaluation. This is not all going to happen the next day and that's were the risk comes in.
Good posts, however after license now we have the business world which is not as predictable. But after license stock will clearly rise nicely.
Then when do you predict the license will be awarded, next week the week after, when?
Once again license is the key. That is it period.
Germany has a great team, who do you think will be in the final. Yes will get license in 2 to 4 weeks. Bill is surprising everyone all the time.
I agree but we need some news either Tuesday or Wednesday. We need a little bump. Yes people are waiting. Let's get some news.
Right now we are in hold mode. Price does seem to be holding. Let's see what happens Tuesday and Wednesday.
Until news comes out do not look for much. It can go up but news is the key. We will get license news. Then will see how high it goes. With day traders to hard to predict pps.
interesting article
Illinois investors jump into marijuana business
3
Print Email
2 hours ago • Kurt Erickson kurt.erickson@lee.net0
Enlarge Photo
SPRINGFIELD — In a sign Illinois' new medical marijuana law could be a gold mine for investors, a politically connected Glenview attorney is hoarding pot-related company names in hopes of cashing in if the business takes off.
Sam Borek, a former college roommate of the lawmaker who sponsored the state's new law, says he reserved the company names to either sell them to others, or to start his own companies.
Included in his list of at least three dozen potential corporations and limited liability companies are Illinois Medical Marijuana Sales Inc., Illinois Cannabis Realty Inc. and Cannabis Medical Centers of Illinois Inc.
Just as political insiders cashed in when Illinois legalized casino gambling in 1990, Borek's maneuvers offer a behind-the-scenes look at the jockeying underway to grab a piece of the newly legalized medical pot business.
Take David Rosen of Chicago, for example. He helped get Gov. Pat Quinn elected in 2010, serving as the Democrat's chief fundraiser. Rosen's also raised campaign cash for Hillary Clinton and Al Gore.
In April, Rosen filed paperwork to open a medical marijuana establishment in Nevada. In a sign he wants to be a player here too, the company name — Waveseer — also has been registered in Illinois.
Rosen did not return multiple telephone messages left at his Chicago office. But Nevada records show a number of Illinoisans who've invested money in Waveseer's venture in Nevada venture, including:
• River Forest attorney Kevin Conway, who has contributed more than $7,300 to Quinn in the past year;
• Marcia Rayman of Big Rock, who gave Quinn $5,000 in September. Her husband, businessman Steven Rayman, has given Quinn $40,000 over the past five years;
• A trust controlled by retired businessman Howard Gottlieb of Evanston, who gave Quinn $40,000 during the 2010 election cycle; and
• Francesca Cooper, the wife of wealthy Edwardsville attorney Jeff Cooper, who helped bankroll a cancer treatment center at the Southern Illinois University School of Medicine in Springfield.
Although the actual implementation of Illinois' new medical marijuana law is still months away, various companies are in talks with communities to try and win the right to grow and dispense the drug.
Under the rules being written to regulate medical marijuana, companies applying to grow and sell it must meet a lengthy list of guidelines, including showing they have the capital to support one of the enterprises.
The applications will then be scored, with the highest score being awarded a franchise. There will be 22 marijuana growing centers and 60 pot dispensaries in the state.
In McLean County, an unnamed company approached LeRoy officials last month about starting a growing facility in the town. Similar entreaties have been made in Tazewell, St. Clair, Warren and Jersey counties.
Some firms have hired lobbyists to help them move forward in becoming one of the limited number of growing facilities and dispensaries. Jack Lavin, who was Quinn's chief of staff, is lobbying on behalf of a medical marijuana business owned by Effingham attorney Matt Hortenstine and Springfield lobbyist Christopher Stone.
Salveo Health & Wellness, a company pursuing a growing operation in Warren County, has enlisted Mark Boozell, former Gov. Jim Edgar's chief of staff, as its lobbyist.
Borek has political connections, too. In 2012, the Chicago Tribune reported he was a college roommate of state Rep. Lou Lang, D-Skokie, who sponsored the landmark medical marijuana legislation. Records show Borek has given Lang's campaign fund $15,000 over the past 20 years.
Each of the company names he's registered typically contains some reference to the drug that eventually will be made available to Illinoisans who have certain medical conditions.
Based on standard state filing fees, Borek has spent at least $2,300 to reserve the various names for up to 90 days. If he wants to extend the time period, he'd have to pay a similar amount for all of the possible companies.
But just as there are no guarantees any of the entities will win the right to run a dispensary or growing operation, there are other pitfalls for investors.
In an interview, Borek said he recently tried to open checking accounts but was turned down because the banks are worried about being penalized under federal law if they deal with marijuana growers and sellers.
"We've got some checks to invest from investors and we can't deposit them," he said.
Under one scenario, he said he potentially could remove the words "marijuana" or "cannabis" from his proposed companies to appease the banks.
"We're looking at some names now. We've got some good alternatives," said Borek.
Copyright 2014 stltoday.com. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
Tags
Lets get some research fast.
Interesting article re research
Better Marijuana Stock: GW Pharma vs Insys
By Todd Campbell | More Articles | Save For Later
June 15, 2014 | Comments (0)
GW Pharma (NASDAQ: GWPH ) and Insys (NASDAQ: INSY ) hope to create effective treatments based on chemical cannabinoids found in marijuana. GW Pharma is already selling a THC synthetic drug as a treatment for Multiple Sclerosis spasticity in 11 countries, and the company is conducting a range of studies evaluating cannabinoids therapeutic value across cancer pain and diabetes. Meanwhile, Insys is working on a new version of Marinol, a long-standing THC-based drug used to prevent nausea in chemotherapy patients.
Investor interest in these new therapies has caused shares in both companies to spike in the past year, but is one a better buy than the other?
GWPH Chart
GWPH data by YCharts
Big hype = big valuation
Sales of GW Pharma's Sativex totaled just $13 million in the first quarter, giving it an annualized sales run rate of roughly $60 million and a price to sales valuation north of 20. That's a heady valuation for any company, particularly one that lost more than $8 million last quarter.
For example, when Amgen bought Onyx Pharma in 2013 it paid about 17 times sales. When Sanofi bought Viropharma last year it paid about 10 times sales and when Actavis bought Forest Labs earlier this year it paid 7 times sales.
In comparison, sales of Insys' opioid pain killing drug Subsys have jumped over 300% in the past year to $40 million in the first quarter. That gives Insys a price to sales valuation of roughly 5. In addition to having a lower price to sales ratio, Insys has another advantage over GW Pharma: it makes money. While Insys' net income has reached nearly $50 million over the past 12 months, GW Pharma has notched $20 million in losses.
GWPH Net Income (TTM) Chart
GWPH Net Income (TTM) data by YCharts
Delivering on potential
A lot of the valuation awarded to both these companies is based on future sales, not historical sales.
At GW Pharma, investor enthusiasm stems in part from the potential to expand Sativex's label to include other important indications beyond MS. The Food and Drug Administration recently awarded Sativex fast-track designation, for example, for use in treating cancer pain. Sativex is currently in phase 3 trials for that indication and GW Pharma expects to report data from those trials later this year.
GW Pharma is also exploring Sativex as a diabetes treatment and recently announced that the FDA has awarded fast-track status to Epidiolex, a drug for use in a rare form of epilepsy in children.
Whether GW Pharma's trials prove its cannibinoid treatments effective in these new indications remains to be seen; however, even if it does, investors may want to keep their projections in check. The indication for cancer pain is a second line therapy for those who don't respond to opioids, not a first line treatment. Given that companies like Insys (with Subsys) are creating effective opioids, its unclear how much of the market GW Pharma can capture. GW Pharma's potential for Epidiolex may also be small. Dravet Syndrome, the form of epilepsy for which Epidiolex received fast-track status, is uncommon with just 5,400 patients in the U.S. and 6,700 in Europe.
At Insys, Subsys has already captured significant market share from the market share leaders. Teva Pharmaceuticals' Actiq and Fentora opioid treatments controlled nearly 75% market share in treating breakthrough cancer pain just two years ago, but Subsys' launch has helped cause their market share to fall to less than 35% exiting the first quarter.
Insys thinks it can similarly reshape the market for Marinol, a drug given to prevent nausea in cancer and HIV patients. The market for Marinol peaked above $100 million before AbbVie lost patent protection on it and Insys believes a new, better-acting version of Marinol could have similar nine figure potential. Of course, that depends on the FDA giving it a green light. Insys plans to file for that approval before mid year.
Fool-worthy final thoughts
GW Pharma has used investor enthusiasm to shore up its balance sheet, raising $100 million in January through a follow-on stock offering. That brought its cash position to more than $150 million exiting the first quarter and puts it on solid financial footing for ushering drugs in its pipeline through trials and to market.
Insys' cash has also climbed in the past year, but is far less substantial at $40 million. That may not give Insys a lot of wiggle room, particularly given recent concerns over regulator scrutiny of its marketing practices. Similar scrutiny of Teva's opioid treatments eventually resulted in a $400 million settlement back in 2008.
GWPH Cash and Equivalents (Quarterly) Chart
GWPH Cash and Equivalents (Quarterly) data by YCharts
Investors will need a lot of things to go right at GW Pharma to justify its sky-high price to sales, including approvals in more indications. While cheaper, Insys has risk too, including whether fall-out tied to regulator questions derail Subsys success and whether Insys' Marinol formulation gets approved. That said, uncertainty at both companies should, for now, keep all but the most aggressive investors at bay.
I helped my parents buy a bigger house – when I made these 2 clicks!
That’s what Michael M. from Windermere, FL told us about Motley Fool Stock Advisor. “I managed a small brokerage account for my parents. Dad was changing jobs to a position that required him to buy a house... Thanks to the appreciation in Marvel, they were able to buy 3x as much house -- free and clear -- as initially budgeted." Don’t delay! You’re just 2 clicks away from taking CONTROL of your own family’s financial future. Secure our best offer, scoop up three FREE bonus reports, and save a total of $486. Just click here when you’re ready to complete your deal.
Todd Campbell has no position in any stocks mentioned. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may or may not have positions in the companies mentioned. Todd owns Gundalow Advisors, LLC. Gundalow's clients do not have positions in the companies mentioned.
The Motley Fool recommends Apple. The Motley Fool owns shares of Apple. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
When there is license I will sell. I will watch and buy and sell. Cannot prove anything. I had a stock bught for 10 cents went down to 7 cents when it went up to 20 I sold. Within three months it went over a dollar. Now you can use stock to wall paper. What may help fitx is the fact day traders may pump it. Shares can compared to value and to be quite frank hype can be pumped up. Just a went and see mode. Thanks for the posts.